G-CSF accelerates neutrophil recovery after autologous peripheral blood progenitor cell transplantation (aPBPCT), although the optimal timing for its administration is currently unknown. In order to establish the role and the optimal timing of administration of G-CSF after immunoselected CD34
The administration of G-CSF to accelerate haemopoietic recovery following autologous bone marrow transplantation (BMT) [1] [2] [3] [4] and autologous peripheral blood progenitor cell transplantation (aPBPCT) is widely used even if available results are often misleading. [5] [6] [7] [8] [9] In fact, G-CSF after aPBPCT has been shown to significantly promote PMN recovery but has no impact on the duration of hospitaliz-ation, non-prophylactic antibiotics (NPA) and finally on the overall cost of the procedure.
3,10-13 G-CSF at a dose of 5-10 g/kg/day is currently introduced early (day 1) after transplantation although the optimal timing is largely unknown.
14 Attempts to delay G-CSF administration showed promising results in terms of efficacy and cost saving. 15 We investigated the role of early or delayed G-CSF administration after immunoselected CD34 ϩ aPBPCT vs a control group of patients not receiving G-CSF. G-CSF serum levels were also studied during different schedules of G-CSF administration.
Patients and methods

Patients
From December 1994 to June 1998 we studied 21 consecutive patients submitted to immunoselected CD34 ϩ PBPCT: nine female, 12 male, median age 47 (range 18-60), nine NHL, five HD, seven MM. Characteristics of patients, and disease status at transplantation are shown in Table 1 . These patients were randomized into three groups:
Group A (six patients): no G-CSF administration after PBPC reinfusion; Group B (six patients): G-CSF from day ϩ1 until PMN count Ͼ0.5 × 10 9 /l for 3 consecutive days; Group C (nine patients): G-CSF from day ϩ7 until PMN count Ͼ0.5 × 10 9 /l for 3 consecutive days.
As a result of randomization the number of patients is not equal between the three groups with nine patients in group C at the time the study was completed. Due to the small number of patients included in the study no stratification was performed. G-CSF (Lenograstim (rHuG-CSF) ChugaiRhone-Poulenc Rorer, France) was administered s.c. at a standard dose of 263 g/day (one vial) starting on day ϩ1 in group B and on day ϩ7 in group C. G-CSF was discontinued when PMN Ͼ0.5 × 10 9 /l were reached and maintained for 3 consecutive days. Group A did not receive G-CSF after transplantation. The administration of G-CSF from day 7 was chosen according to our previous observations 16 on endogenous G-CSF release after PBPCT in an attempt to amplify physiological G-CSF response to neutropenia. Informed consent was obtained from all patients. The protocol was approved by the Institutional Review Board at Università Cattolica Sacro Cuore.
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Collection of haemopoietic progenitors
PBPC were mobilized and collected after the following mobilizing cycles of chemotherapy: MiCMA (mitoxantrone 10 mg/m 2 day 1, carboplatinum 100 mg/m 2 days 1-4, cytosine arabinoside 2 g/m 2 day 5, methylprednisolone 500 mg/m 2 days 1-5, G-CSF 5 g/kg/day subcutaneously (s.c.) from day 8 until completion of the leukapheretic procedure (LCP)) in nine patients with lymphomas; high-dose cyclophosphamide (7 g/m 2 day 0 and G-CSF 5 g/kg/day s.c. from day 1 until completion of LCP) in 12 patients with myeloma or lymphoma. Mobilizing regimens were adopted independently from the subsequent randomization. LCP started when the peripheral white blood count was greater than 1.0 × 10 9 /l and CD34 ϩ cells in peripheral blood were Ͼ20/l. LCP were continued daily until a minimum harvest of 4 × 10 6 CD34 ϩ /kg was obtained. CD34 ϩ progenitor selection was carried out using the Ceprate SC system (Cellpro, Bothell, WA, USA). Briefly, the product of two consecutive LCP was submitted to positive immunoselection with the Ceprate SC. All patients had a back up of unfractionated PBPC stored in liquid nitrogen. 
Supportive care
Patients were treated in single beds with reverse isolation (nine patients) or single sterile rooms equipped with positive air pressure (12 patients). All patients received: prophylaxis for Pneumocystis carinii pneumonia with trimethoprim-sulfamethoxazole 1 double strength tablet every 12 h until day −1 and afterwards it was restarted once a stable engraftment was achieved; oral ciprofloxacine (500 mg every 12 h) from day −7 until stable granulocyte recovery; acyclovir (500 mg/m 2 ) from day −7 to day ϩ100; oral amphotericin B suspension. If fever developed, body temperature (BT) Ͼ38°C: three blood cultures were obtained from peripheral blood and CVC and chest X-rays were performed. Broad-spectrum antibiotic therapy with amikacin 7.5 mg/kg every 12 h, ceftazidime 2 g every 8 h, vancomycin 15 mg/kg every 12 h or teicoplanin 12 mg/kg every 24 h was empirically started. Amphotericin B 0.5-1.0 mg/kg every 24 h was added in case of persistence of fever (Ͼ72 h). Packed RBC were transfused to maintain the haemoglobin concentration at Ͼ8.0 g/dl and platelet transfusions to keep the platelet count at Ͼ15 × 10 9 /l. All blood products were irradiated with 15 Gy.
End points
During this study we evaluated the following clinical outcomes: time to neutrophil recovery (0.5 × /l, duration of hospitalization, duration of NPA, number of days with BT Ͼ38°C, incidence of sepsis, duration of G-CSF administration (in days), reticulocyte recovery (Ͼ1%), number of packed red blood cell unit (pRBCu) and single donor unit of platelets (SDU) infused.
G-CSF assay
In eighteen of 21 patients plasma samples were obtained before high-dose chemotherapy and during the first month after CD34 ϩ aPBPCT. The day 0 sample was drawn in the morning before PBPCT. Early morning samples were drawn every 3 days from day ϩ2 to day ϩ28. Blood was collected in EDTA and plasma was separated by centrifugation (15 min at 4000 r.p.m.) shortly after collection, aliquoted, and stored at −80°C until used. G-CSF serum levels were detected by sensitive and specific immunoassays (Quantikine, R&D SYSTEMS, British Biotechnology, Oxford, UK). Results are expressed as pg/ml.
Statistical analysis
Six patients were needed in each group in order to have an 80% power to detect a 6.91-days difference in days to neutrophil engraftment. Six, six and nine patients were randomized to the three groups respectively. Kruskal-Wallis one-way ANOVA on ranks test was used to analyze continuous factors. Kruskal-Wallis Z test was adopted as the multiple comparison test. The 2 test was chosen for the analysis of the categorical factors. Statistical significance was defined as P Ͻ 0.05.
Results
Haemopoietic recovery
All results are expressed as a median value. Data are summarized in Table 2 Table 2 Results
End points No G-CSF Early G-CSF Delayed G-CSF Kruskal-Wallis
Days to PMN Ͼ0. /l on day ϩ20.5 (range 15-25), patients in group B on day ϩ11 (range 10-11), patients in group C on day ϩ14 (range 11-17), P = 0.00046; multiple comparison: group A vs group B P = 0.00004, group A vs group C P = 0.0007, group B vs group C P = NS. Time to achieve PMN Ͼ1.0 × 10 9 /l was day ϩ22 (range 16-30), ϩ12 (range 11-13), ϩ15 (range 12-34), respectively, in groups A, B, C, P = 0.001: group A vs group B P = 0.003, group A vs group C P = 0.04, group B vs group C P = NS (Figure 1) . As shown in Figure 1 no other statistical differences were detected. Median duration of G-CSF administration was 11.5 days (range 10-15) in group B, 12 days (range 4-48) in group C (P = 0.56). In Figure 2a and b are shown the relationship between CD34 ϩ cell dose and the PMN and platelet recoveries.
Microbiological documented infections
Eleven episodes of sepsis occurred in eight patients. Sepsis was defined as fever Ͼ38°C with a single positive blood culture for any organism except for coagulase-negative staphylococci, for which, two consecutive positive blood cultures were considered significant as reported by Mossad et al. 17 In eight episodes, the etiological agent was a Grampositive microorganism (Staphylococcus epidermidis six, Staphylococcus hominis one, Streptococcus mitis one); in two cases a Gram-negative microorganism was isolated (Escherichia coli one, Chryseobacterium indologenes one); there was one fungal sepsis by Candida guillermondi. ( Table 3 ). The majority of organisms were isolated between days ϩ4 and ϩ10 (range 4-22). Neutropenia (PMN Ͻ0.5 × 10 9 /l) was present in nine cases of sepsis while in two cases, sepsis developed with a normal PMN count. Overall, sepsis occurred in 4/6 patients in group A (66.6%), compared with 2/6 patients in group B (33.3%) and 2/9 patients in group C (22.2%) (P = 0.21).
G-CSF assay
All results are expressed as a median value. Patients not submitted to G-CSF administration (group A) achieved a peak serum level of 528 pg/ml (range 384-864) on day ϩ7 while patients submitted to G-CSF from day ϩ1 achieved Table 3 Microrganisms isolated
Microrganism isolated No. isolation % isolation
Staphylococcus epidermidis 6 5 4 Staphylococcus hominis 1 9 Streptococcus mitis 1 9 Escherichia coli 1 9 Chryseobacterium indologenes 1 9 Candida guillermondi 1 9 a peak serum level of 6362.5 pg/ml (range 5504-7111) on day ϩ11 and the peak serum level was 4060 pg/ml (range 1509-20 000) at day ϩ14 in patients submitted to G-CSF administration from day ϩ7. In patients submitted to G-CSF wide fluctations were observed as documented by the high values of standard deviation (s. d.) . In all patients G-CSF serum levels returned to baseline values by day ϩ17 (Figure 2) . Early or delayed G-CSF administration results in G-CSF peak serum levels 7 (early)-12 (delayed)-fold greater than endogenous response to neutropenia (Figure 3) . No correlation was found in PMN recovery and peak of G-CSF serum level.
Discussion
Several trials have shown that the use of G-CSF after aPBPCT accelerates the time to neutrophil recovery although the clinical and economical impact of such an approach is still controversial. 6, 8, 9, 18 Recently, questions have been also raised about the optimal timing of G-CSF administration after PBPCT. Some recent data showed that G-CSF could be safely delayed after PBPCT resulting in a reduction of drug exposure and cost savings without compromising haemopoietic recovery. 15, 19, 20 Little is known about the use of G-CSF after immunoselected CD34 ϩ aPBPCT. In this setting the procedure virtually abrogates the early haemopoietic recovery due to the abundance of committed progenitors in the leukapheresis product and a delay in the haemopoietic recovery is thus expected. In this study we report three groups of patients affected by haematological malignancies submitted to CD34 ϩ aPBPCT, in which early or delayed G-CSF was compared to no G-CSF support as shown in Table 1 . Time to PMN recovery was significantly shorter when early or delayed G-CSF was administered after transplantation compared to PMN recovery in patients not receiving G-CSF . These data are similar to those observed after unmanipulated PBPCT. 3, 9, 11 Interestingly, the number of days with PMN Ͻ0.1 × 10 9 /l was not influenced by G-CSF administration along with time to platelet counts Ͼ50 × 10 9 /l and Ͼ100 × 10 9 /l, length of hospitalization, duration of NPA, number of days with BT Ͼ38°C, incidence of sepsis, duration of G-CSF adminis- tration (in days), reticulocyte recovery (Ͼ1%), number of pRBCu and SDU infused. Furthermore, the delay in administration of G-CSF did not produce any advantage in terms of haemopoietic recovery compared to early G-CSF. In fact, the median length of G-CSF administration was superimposable between the two groups. This observation is in contrast to what is observed after unmanipulated PBPCT. 15, 20 We also performed G-CSF serum level assays during PBSCT to recognize the entity and the behaviour of the endogenous production of G-CSF levels after CD34 ϩ PBPCT and the serum level achievable when exogenous G-CSF is administered at a standard dose of 263 g/day from day ϩ1 or from day ϩ7. The endogenous G-CSF serum level was consistently lower in patients after CD34 ϩ PBPCT not receiving this growth factor compared to patients submitted to unfractionated PBPCT, 16 thus resulting in an inappropriate G-CSF production in response to neutropenia after CD34 ϩ PBPCT and providing a strong rationale for G-CSF support. The defective endogenous production of G-CSF could be explained by the depletion of lymphoid and accessory cells from the inoculum and it may account for the delayed haemopoietic recovery despite an adequate content of CD34 ϩ cells in the graft in the group of patients not receiving G-CSF after transplantation. Moreover, the endogenous G-CSF response was also inadequate considering the high rate of infection, although this did not reach statistical significance. On the other hand, when G-CSF was administered, serum levels resulted in a 7-to 12-fold increase over the control group suggesting that a different approach could be carried out by reducing daily dose or extending the interval between the doses. In conclusion, G-CSF administration after CD34 ϩ aPBPCT significantly accelerated the time to PMN Ͼ0.5 × 10 9 /l reversing the defective and inconsistent endogenous production of G-CSF but had no impact on severe neutropenia (PMN Ͻ0.1 × 10 9 /l) and on the other endpoints, ie length of hospitalization. Delayed G-CSF was not detrimental to haematological recovery but did not decrease the overall cost related to exogenous supplementation of the growth factor. These results need to be confirmed in a larger group of patients since their applicability may extend to a variety of graft engineering techniques requiring stem cell separation and manipulation.
